Recent Updates
Recently added Catalysts
CYTK Negative Sentiment Score: 25/100

Cytokinetics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Cytokinetics, Incorporated - CYTK

Key Takeaway: Cytokinetics, Incorporated is facing a class action lawsuit for allegedly failing to disclose material information related to its securities. Investors who incurred losses of over $100,000 during the specified Class Period from December 27, 2023, to May 6, 2025, must file lead plaintiff applications by November 17, 2025. The lawsuit pertains to the company's handling of its new drug application for aficamten and its interactions with the FDA, during which significant discrepancies were identified that affected stock valuation. The ongoing case is noted as Seidman v. Cytokinetics, Incorporated, et al., No. 25-cv-07923.

Market Sentiment Analysis

CONCERNS & RISKS

  • Cytokinetics faces a class action lawsuit related to undisclosed information.
  • The company did not convene an FDA advisory committee for its new drug application.
  • Cytokinetics' share price fell to $33.04 following negative news.

Full Press Release Details

NEW ORLEANS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 17, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cytokinetics, Incorporated (NasdaqGS: CYTK), if they purchased or otherwise acquired the Company’s securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Cytokinetics investors should visit us at https://www.claimsfiler.com/cases/nasdaq-cytk or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Cytokinetics and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On March 10, 2025, the Company disclosed that the U.S. Food and Drug Administration (“FDA”) had decided not to convene an advisory committee meeting to review the Company’s New Drug Application (“NDA”) for its aficamten product. Then, on May 6, 2025, the Company disclosed that it had held multiple pre-NDA meetings with the FDA discussing safety monitoring and risk mitigation but chose to submit the NDA without a Risk Evaluation and Mitigation Strategy, instead relying on labeling and voluntary education materials.
On this news, the price of Cytokinetics’ shares fell, closing at $33.04 per share on May 7, 2025.
The case is Seidman v. Cytokinetics, Incorporated, et al., No. 25-cv-07923.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Securities Litigation

Frequently Asked Questions

What is the deadline to file lead plaintiff applications?

The deadline to file lead plaintiff applications is November 17, 2025.

What period does the securities class action cover?

The class action covers those who acquired Cytokinetics securities from December 27, 2023, to May 6, 2025.

Where is the class action lawsuit pending?

The lawsuit is pending in the United States District Court for the Northern District of California.

What caused Cytokinetics' share price to fall?

The share price fell after the company disclosed FDA decisions regarding their NDA for aficamten.

How can investors get information on securities class actions?

Investors can visit ClaimsFiler.com for information and resources on securities class actions.

Last updated: Oct 30, 2025